Building on five decades of manufacturing heritage from ROVI, the company now operates with a sharpened focus on its role as a specialized contract development and manufacturing organization. CEO Javier López-Belmonte noted that the rebranding effort is designed to capture the firm's evolution into a modern partner capable of balancing high-volume production with the personalized service of a family-led business.

ROIS currently manages over 800 million units of annual capacity, specializing in complex injectables such as biologics, biosimilars, and mRNA-based therapies. The company’s technical infrastructure includes high-containment OEB5 facilities, lyophilization, and cytotoxic manufacturing, serving clients across more than 75 international markets. Attendees at CPHI Milan can view the new identity firsthand at booth 10C49 through October 8, where the company is showcasing its integrated service model and global reach.